AB Akola Group twelve months: the second-best year in the Group‘s history

Financial Performance - The consolidated revenue of AB Akola Group for the 2024/2025 financial year exceeded EUR 1,580 million, representing a 4.9% increase year-over-year [1][3] - Consolidated EBITDA for the twelve months amounted to EUR 111 million, marking a 51.5% increase year-over-year, while net profit increased by 51.4% to EUR 62.6 million [2][3] - The fourth quarter revenue reached EUR 414 million, an 8.6% increase from EUR 381 million in the previous year, with net profit rising to EUR 31 million from EUR 10 million [3][4] Segment Performance - The 'Food Production' segment generated EUR 449.1 million in revenue, with operating profit increasing by 95.6% to EUR 40 million [5] - The poultry business significantly contributed to the Group's success, with gross profit soaring by 103% to EUR 68.9 million due to favorable market conditions [6][8] - The 'Partners for Farmers' segment generated EUR 1,151.3 million in revenue, with gross profit reaching EUR 92.6 million, showing improvement over the previous year [11] Agricultural Operations - The 'Farming' segment generated EUR 47.6 million in revenue, a 9.3% increase compared to the previous year, with gross profit at EUR 12.9 million [15] - The agricultural companies harvested 3% more than the previous year, driven by strong winter crop yields, despite weaker summer crops due to drought [16] Market Trends - Consumer preference for sustainable protein sources is rising, while alternative protein prices remain elevated [7] - The EU broiler production costs have remained stable or slightly lower, suggesting improved producer margins [8] - There is a growing appreciation for higher quality poultry meat raised without antibiotics in Lithuania and Latvia, although competition is intensifying [9] Other Business Activities - The 'Other Products and Services' segment generated EUR 20.8 million in revenue, with a gross profit of EUR 4.1 million, but recorded an operating loss of EUR 400 thousand [17] - Pet food sales volumes declined by 11%, while veterinary pharmaceutical revenue increased by 19% [18]